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Abstract Endoluminal treatment of infrapopliteal artery
lesions is a matter of controversy. Bioabsorbable stents are
discussed as a means to combine mechanical prevention of
vessel recoil with the advantages of long-term perspectives.
The possibility of not having a permanent metallic implant
could permit the occurrence of positive remodeling with
lumen enlargement to compensate for the development of
new lesions. The present study was designed to investigate
the safety of absorbable metal stents (AMSs) in the infra-
popliteal arteries based on 1- and 6-month clinical follow-
up and efﬁcacy based on 6-month angiographic patency.
One hundred seventeen patients with 149 lesions with
chronic limb ischemia (CLI) were randomized to implan-
tation of an AMS (60 patients, 74 lesions) or stand-alone
percutaneous transluminal angioplasty (PTA; 57 patients,
75 lesions). Seven PTA-group patients ‘‘crossed over’’ to
AMS stenting. The study population consisted of patients
with symptomatic CLI (Rutherford categories 4 and 5) and
de novo stenotic ([50%) or occlusive atherosclerotic dis-
ease of the infrapopliteal arteries who presented with a
reference diameter of between 3.0 and 3.5 mm and a lesion
length of\15 mm. The primary safety endpoint was
deﬁned as absence of major amputation and/or death within
30 days after index intervention and the primary efﬁcacy
endpoint was the 6-month angiographic patency rate as
conﬁrmed by core-lab quantitative vessel analysis. The
30-day complication rate was 5.3% (3/57) and 5.0% (3/60)
in patients randomized for PTA alone and PTA followed
by AMS implantation, respectively. On an intention-to-
treat basis, the 6-month angiographic patency rate for
lesions treated with AMS (31.8%) was signiﬁcantly lower
(p = 0.013) than the rate for those treated with PTA
(58.0%). Although the present study indicates that the
AMS technology can be safely applied, it did not demon-
strate efﬁcacy in long-term patency over standard PTA in
the infrapopliteal vessels.
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Introduction
Over the last years, a gradual change in treatment strategy
for critical limb ischemia (CLI) has been observed: the
endovascular approach has become more and more
accepted as a valid alternative for surgical intervention [1].
The BASIL trial participants played a pivotal role in this
shift toward the minimal invasive approach for patients
with CLI due to infrainguinal disease. They were the ﬁrst
to publish results of a controlled, randomized study com-
paring bypass surgery results to those of percutaneous
transluminal angioplasty (PTA) in CLI patients that yielded
similar outcomes for both treatments, with angioplasty
being the less expensive alternative in the short term [2].
The latter resulted in the statement in the renewed TASC-II
guidelines that there is increasing evidence to support a
recommendation for PTA in patients with CLI and infra-
popliteal artery occlusion [3].
For a complete list of authors and their contributions, see the Table 6.
M. Bosiers (&)   On Behalf of the AMS INSIGHT Investigators
Department of Vascular Surgery, AZ St-Blasius, Kroonveldlaan
50, 9200 Dendermonde, Belgium
e-mail: marc.bosiers@telenet.be
123
Cardiovasc Intervent Radiol (2009) 32:424–435
DOI 10.1007/s00270-008-9472-8Although the use of stents is common in other peripheral
vessels, the application of stents in the infrapopliteal bed
remains highly controversial. The fear that early throm-
bosis and late luminal loss due to intimal hyperplasia
formation potentially lead to insufﬁcient long-term patency
rates can explain the reluctance on implanting stents in
these small-diameter vessels. Although the limited evi-
dence available suggests very acceptable outcomes using
either passive coated stents (PCSs) [4], balloon-expandable
drug-eluting stents [5–8], or self-expanding nitinol stents
[9–12], target lesion revascularization (TLR) is still
required in a signiﬁcant percentage of patients to enable
limb salvage. The permanent presence of an artiﬁcial
implant is believed to be the potential trigger for late
restenosis. Recently the stenting technology has moved
toward the development of temporary implants composed
of biocompatible materials which mechanically support the
vessel during the period of high risk for recoil and then
completely degrade on the long-term perspective [13–19].
Therefore, bioabsorbable stents are discussed as a means to
combine mechanical prevention of vessel recoil with var-
ious advantages of the long-term perspective compared to
permanent implants, including the possibility of late out-
ward vessel remodeling, and improved reintervention
options [18]. The bioabsorbable magnesium-alloy stent
developed by BIOTRONIK AG was the ﬁrst of its kind for
which it was proven that it could be implanted safely in
infrapopliteal [17, 18, 20] and human coronary arteries [13,
21, 22] and that it was absorbed in the intended time frame.
In the absorbable metal stent (AMS) below-the-knee study
[20], Bosiers et al. presented the ﬁrst clinical results using
AMSs for treatment of infrapopliteal lesions in 20 patients
with CLI. After 6 months, the resulting values for primary
clinical patency and limb salvage indicated a promising
performance for the treatment of below-the-knee lesions in
CLI patients. Moreover, in the PROGRESS-AMS study the
authors proved that bioabsorbable magnesium stents can
achieve immediate angiographic results similar to the
results with other permanent metal stents and is safely
degraded after 4 months [13] in native coronary artery
single de novo lesions.
Based on these ﬁndings, the study was set up to give
further proof of AMS safety and efﬁcacy for the treatment
of CLI, and the AMS INSIGHT (Bioabsorbable Metal
Stent Investigation in Chronic Limb Ischemia Treatment)
randomized controlled trial was initiated. Therefore, in this
article, safety results based on 1- and 6-month clinical
follow-up and efﬁcacy data based on 6-month angiographic
results for the AMS INSIGHT in patients with CLI are
presented and discussed (see Table 6 for a complete list of
authors and their contributions). The primary aim of the
study was to prove the superiority of the AMS stent
compared to PTA alone for infrapopliteal indications.
Materials and Methods
The AMS INSIGHT is a prospective, multicenter, ran-
domized study, designed to evaluate the safety and
performance of the ﬁrst-generation AMS for the treatment
of infrapopliteal lesions in patients with CLI. The results
after AMS implantation are compared with the results after
PTA alone.
The study was conducted according to the Declaration
of Helsinki on investigation in humans and was approved
by the institutional ethics committees at the different par-
ticipating institutions. All patients provided written
informed consent.
Patients
The study population consisted of patients with symp-
tomatic CLI (Rutherford categories 4 and 5). They were
eligible if they had de novo stenotic ([50%) or occlusive
atherosclerotic disease of the infrapopliteal arteries and
presented with a reference vessel diameter of between 3.0
and 3.5 mm and a lesion length of\15 mm (i.e., less than
one stent length). An overview of all inclusion and
exclusion criteria is presented in Table 1. Based on the
diffusive nature of lesions and the difﬁculties during the
enrollment process, the initial inclusion criterion for lesion
length was expanded to be\20 mm. Moreover, the initial
criterion considering a maximum of two lesions in one or
more infrapopliteal vessel was also modiﬁed to allow the
PTA treatment of other infrapopliteal lesions in nontarget
vessels outside of the current study.
From June 30, 2005 (day of ﬁrst patient enrollment), to
February 2, 2007 (day of last patient enrollment), 117 CLI
patients from 13 clinical sites in Belgium, the Netherlands,
Austria, and Germany were enrolled in the trial. Fifty-
seven patients were randomized to the PTA-only group,
and 60 to the AMS group. In total, 149 lesions were treated
in 117 patients, which resulted in a total of 74 lesions in the
AMS arm and 75 lesions in the PTA control arm (Fig. 1).
The mean age of patients enrolled in the study was
73.1 ± 8.5 (range, 53–91) and 74.7 ± 7.8 (55–87) years in
the PTA and AMS groups, respectively. Patient demo-
graphics are described in more detail in Table 2. Nicotine
abuse was noted in 26 (45.6%) and 24 (40.0%) patients in
the PTA and AMS groups, respectively. Comorbidities
were arterial hypertension in 51 (89.5%) and 51 (85.0%),
hyperlipidemia in 35 (61.4%) and 32 (53.3%), and diabetes
mellitus in 39 (68.4%) and 43 (71.7%) patients in the PTA
and AMS groups, respectively. In addition, Table 2 reports
the patient distribution according to the Rutherford classi-
ﬁcation. The baseline characteristics of the randomized
patients are statistically not different in the two treatment
groups except for gender (p = 0.04).
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The devices used in the study were the ﬁrst-generation
AMS and the Pleon Explorer angioplasty balloon catheter,
both developed by BIOTRONIK AG (Switzerland). The
ﬁrst-generation AMS is a balloon-expandable, tubular laser
slotted, electropolished stent made of a bioabsorbable
magnesium (Mg) alloy [13]. The ﬁrst-generation AMS
design is a special one that takes into consideration the
speciﬁc mechanical properties of the bioabsorbable Mg
alloy. The mechanical properties of the Mg stent are sim-
ilar to those of permanent stainless-steel stents, including a
Table 1 Inclusion and
exclusion criteria
Note: PTA, percutaneous
transluminal angioplasty
a Expanded during course of
investigation to\20 mm
b Modiﬁed to allow PTA
treatment of other infrapopliteal
lesions in nontarget vessels
outside of the current study
Inclusion criteria
Stenotic ([50%) or occlusive atherosclerotic disease of the infrapopliteal arteries
Length of lesion\15 mm (less than one stent length)
a
Reference vessel diameter 3.0–3.5 mm
A maximum of two lesions in one infrapopliteal vessel treated in the study,
or in two vessels of two different legs
b
Symptomatic critical limb ischemia (Rutherford 4 and 5)
Patient C50 years of age
Life expectancy of[6 months
No child-bearing potential or negative serum pregnancy test within 7 days of the index procedure
Patient willing and able to return at the appropriate follow-up times for the duration of the study
Patient provision of written patient informed consent that is approved by the ethics committee
Exclusion criteria
Patient refusal of treatment
Reference segment diameter not suitable for available stent design
Length of lesion requiring more than one stent implantation
Previously implanted stent(s) or PTA at the same lesion site
Lesion lying within or adjacent to an aneurysm
Inﬂow-limiting arterial lesions left untreated
Patient has a known allergy to heparin, aspirin
, or other anticoagulant/antiplatelet therapies
or a bleeding diatheses, or is unable, or unwilling, to tolerate such therapies
Patient taking phenprocoumon (Marcumar)

Patient history of prior life-threatening contrast medium reaction
Patient currently enrolled in another investigational device or drug trial
Patient currently breastfeeding, pregnant, or intending to become pregnant
Patient mentally ill or retarded
Patient liable for military or civilian service
Fig. 1 Flowchart for patient distribution after randomization
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123high collapse pressure (0.8 bar), low elastic recoil (\8%),
and minimum amount of shortening after inﬂation (\5%).
The stents (10, 15, and 20 mm in length; 3.0 and 3.5 mm in
diameter), premounted on a low-compliance fast-exchange
delivery balloon catheter, were deployed after predilatation
of the lesion. The two radio-opaque markers on the balloon
ends were used for precise positioning since the AMS itself
is not visible under ﬂuoroscopy. The delivery system is
compatible with guiding catheters with an inner diameter
of at least 0.07 in. (1.78 mm). Magnesium was chosen as
the main alloy component because of its hypothrombo-
genic properties [23] and good predictable local tissue
tolerance. Additionally, the mechanical properties and
corrosion of Mg alloy are controllable under physiologic
conditions [14, 23] and match the high requirements for
bioabsorbable stent implants.
The Pleon Explorer fast-exchange balloon catheter, used
for the angioplasty arm (PTA group) and for lesion pred-
ilation in the stenting group, is designed for dilatation of
stenotic segments in infrapopliteal arteries. The balloon has
the same dimensions as the AMS (10, 15, and 20 mm in
length and /3.0 and /3.5 mm in diameter). The working
length of the Pleon Explorer balloon catheter is 140 cm.
The inner distal lumen permits the use of guidewires of
diameter 0.014 in. to facilitate advancement of the catheter
to and through the lesions to be dilated. The Pleon Explorer
balloon catheter is compatible with either coronary guiding
catheters with an inner diameter of C0.056 in. (1.42 mm)
or introducers with a minimal size of 5 Fr and length of
45 cm or 90 cm for antegrade or crossover procedure,
respectively.
Procedural Description
Patients were randomly assigned to and treated with either
PTA or AMS implantation. The randomization list was
generated using PROC PLAN of SAS (Statistical Analysis
Software). Sequentially numbered sealed envelopes con-
tained information on the treatment to be applied. The
sealed envelopes were opened only after the lesion was
successfully crossed with the guidewire, and then patients
were allocated either to stent or to PTA alone.
Vascular access was achieved, and all inﬂow-limiting
lesions were treated according to the investigator’s stan-
dard clinical practice. Before lesion treatment, diagnostic
angiography of the lesion area and distal runoff were per-
formed. A long sheath or guiding catheter was used to
advance the interventional catheters for the Pleon Explorer
fast-exchange balloon catheter or the AMS delivery
system.
In patients randomized to stenting, after measurement
and then selection of a suitable balloon length, the lesion
was predilated with the Pleon Explorer balloon under
angiographic control. Predilatation was mandatory in this
study. After dilatation, the stenosed area was treated by one
AMS implant. Postdilatation was allowed at the discretion
of the physician, for cases where angiographic control
revealed suboptimal apposition of the AMS to the vessel
wall or ﬂow-limiting residual stenosis.
In patients randomized to PTA, the lesion was dilated
with the Pleon Explorer balloon under angiographic con-
trol. In cases in which the residual stenosis after procedure
was estimated to be[50%, balloon inﬂation was repeated
and prolonged. If the stenosis persisted to be[50% or a
ﬂow-limiting dissection occurred, the patient underwent
implantation of the AMS study stent and ended up in the
crossover group.
Intra-arterial digital subtraction angiography (DSA) was
performed to assess the different procedural steps. Imme-
diate preprocedural and postprocedural images were
obtained to assess lesion characteristics (lesion location,
lesion length, stenosis percentage, outﬂow condition, etc.)
and immediate postprocedural success, respectively, to
document the ﬁnal procedural outcome (Fig. 2). Angio-
graphic images were shipped to an independent core lab for
quantitative vessel analysis (QVA). Postprocedural vessel
runoff was conﬁrmed by angiography.
Table 2 Patient demographic distribution and patient baseline data at
randomization in the AMS INSIGHT
PTA only AMS p-
value
Age
Mean ± SD year 73.1 ± 8.5 74.7 ± 7.8 0.31
a
N/Ntotal; min–max 57/117; 53–
91
60/117; 55–
87
Male, N/Ntotal (%) 41/57 (71.9) 31/60 (51.7) 0.04
b
Female, N/Ntotal (%) 16/57 (28.1) 29/60 (48.3)
Diabetes mellitus, N/Ntotal
(%)
39/57 (68.4) 43/60 (71.7) 0.84
b
Smoking, N/Ntotal (%) 26/57 (45.6) 24/60 (40.0) 0.58
b
Hyperlipidemia, N/Ntotal (%) 35/57 (61.4) 32/60 (53.3) 0.45
b
Hypertension, N/Ntotal (%) 51/57 (89.5) 51/60 (85.0) 0.58
b
Rutherford category, N/Ntotal (%)
4 16/57 (28.1) 16/60 (26.7) 0.87
c
5 41/57 (71.9) 44/60 (73.3)
Ankle-brachial index
Mean ± SD (N) 0.7 ± 0.3
(44)
0.8 ± 0.5
(46)
0.21
a
Min–max 0.2–1.8 0.3–2.5
Note: PTA, percutaneous transluminal angioplasty; AMS, absorbable
metal stent
a t-test
b Fisher exact test
c Wilcoxon test
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The primary safety endpoint of the AMS INSIGHT was
deﬁned as the absence of clinical complications at 1 month
postprocedure. Complications were deﬁned as major
amputations or any cause of death. Major amputations were
deﬁned as amputations at or above the ankle. The primary
efﬁcacy endpoint of this study was to analyze and compare
the 6-month angiographic patency rate after PTA alone
or PTA followed by AMS implantation in patients with
stenotic or occlusive atherosclerotic disease of the infra-
popliteal arteries. Patency was deﬁned as the absence of a
hemodynamically signiﬁcant restenosis ([50%) docu-
mented by digital subtraction angiography and conﬁrmed
by the core-lab QVA.
The secondary endpoints deﬁned in the study design
included (1) immediate angiographic procedural success,
which was deﬁned in both therapy groups as\30% ﬁnal
residual diameter stenosis of the target segment based on
visual assessment of the planned treatment area; (2) late
lumen loss (LLL) as diagnosed at 6-month angiographic
control and deﬁned by the difference between the in-stent
minimal lumen diameter (MLD) postprocedure and the
MLD at follow-up measured with angiography; (3) the
limb salvage rates, deﬁned as lack of major amputations at
the different prescheduled follow-up visits until 12 months
after index intervention; and (4) the primary patency rates
at each visit as determined by color ﬂow Doppler ultra-
sound (CFDU) and deﬁned as either the absence of a
hemodynamically signiﬁcant restenosis ([50%) derived
from the ratio of the peak systolic velocity (PSV) at the
lesion segment to that at the proximal part [24], a major
amputation, or a TLR.
The current article is limited to the analysis of the
endpoints until 6 months.
Medication
Clopidrogel saturation was obtained prior to the procedure.
Heparin was administered during the procedure according
to standard practice. The postprocedure antithrombotic
regimen was that used according to the protocol (Clopi-
dogrel, 75 mg daily for 1 month; and aspirin, 75–300 mg
daily lifelong).
Follow-Up Visits and Study Speciﬁc Investigations
After the intervention, all patients were closely monitored
and controlled before discharge and at 1, 6, and 12 months
after primary intervention, or when clinically indicated. At
every visit (regular follow-up or any clinically indicated
interim visit), clinical investigations were performed; these
examinations included medication history assessment,
clinical categorization of CLI, and the occurrence of in-
stent restenosis investigated by CFDU. Additionally, at
6 months after the index intervention, patients were
requested to undergo an intra-arterial DSA control. DSA
images were analyzed at an external angiographic core
laboratory (Jeffrey Popma, M.D., Brigham and Women’s
Hospital, Boston, MA). Angiograms were performed
according to the instruction of the core lab. A radio-opaque
ruler was positioned in the imaging plane for precise size
calibration. The ruler was present in all ﬁlm analyzed
sequences, including the follow-up. Moreover, images
were obtained using the ‘‘best view’’ of stenosis, and
additionally, a second view was considered in all ﬁlm
sequences to be analyzed. Finally, the identical imaging
parameters were set and considered for the 6-month fol-
low-up DSA control.
CFDU was performed at screening, before hospital
discharge, and at scheduled 1-, 6-, and 12-month follow-up
visits and any interim visit. Each examination comprised
measurements of the maximum peak systolic velocity
(PSV) 1 cm proximal to the lesion (‘‘prestenotic’’), within
the lesion (‘‘intrastenotic’’), and 1 cm distal to the lesion
(‘‘poststenotic’’). The ratio of the maximum intrastenotic
PSV to the maximum prestenotic PSV (proximal peak
velocity ratio PVRproximal = PSVintrastenotic/PSVprestenotic)
determined the percentage stenosis by means of a look-up
table [24]. For example, a PVR ratio C2.4 corresponds to a
stenosis rateof[50–59%.
The 6-month results are composed of measurements
performed at predeﬁned protocol visits (6 months ± 30
days, including out-of-window visits) and any clinically
indicated follow-up visits performed prior to 6 months ±
30 days due to nonpatency.
Fig. 2 Angiographic control of (A) a pretreated 80% stenosis of the
tibioﬁbular trunk, with (B) 5% residual stenosis after AMS implan-
tation and (C) 36% in-stent restenosis at 6 months after index
procedure
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The sample size calculation for this study was based on the
hypothesis of a superior efﬁcacy of the ﬁrst-generation
AMS system in maintaining a patent vessel lumen at
6 months compared to PTA alone. We assumed at
6 months a patency rate of 50% in the PTA arm and a
clinical relevance effect of 25% in the AMS arm. With
acceptance of a 10% dropout rate, a crossover rate of 30%
in the PTA arm, a two-sided signiﬁcance level a of 0.05,
and 80% statistical power, a total of 117 patients were
required.
Descriptive data summaries were used to present and
summarize the collected study data. For categorical vari-
ables (e.g., gender), frequency distribution and cross
tabulation were considered. For numeric variables (e.g.,
patient age), minimum, maximum, mean, median, and
standard deviation were calculated. For all variables a 95%
conﬁdence interval for the relevant parameters of the
underlying distribution were calculated. To show superi-
ority regarding safety and efﬁcacy endpoints of AMS over
PTA alone, life tables according to the method of Kaplan–
Meier are presented for all time-dependent events. To
test differences in the cumulative survival probabilities
between the study groups, the log-rank test was performed.
To show statistical difference for the non-time-dependent
variables, a t-test was performed for continuous variables.
In the case of nonnormally distributed variables, a Wilco-
xon test and, in the case of dichotomuous variables, a
Fisher exact test were performed. Data were analyzed
according to both ‘‘intention to treat’’ (ITT), i.e., the initial
randomization schedule and ‘‘on-treatment’’ (OT), i.e., the
actual treatment received. All statistical analyses were
performed using SAS version 9.1 software.
Results
In the AMS INSIGHT a total of 117 patients (149 lesions)
are enrolled and randomized to undergo endovascular
treatment of infrapopliteal lesions in patients with CLI. As
shown in Fig. 1, randomization assigned 57 patients (75
lesions) to PTA and 60 patients (74 lesions) to AMS. With
respect to lesion morphology, the resulting patient cohorts
were well matched. Description of the lesion morphology
was based on the preprocedural angiographic images and is
reported in Table 3. The reference vessel diameter (RVD)
was 2.7 ± 0.5 (range, 1.4–4.4) and 2.6 ± 0.5 (range, 1.5–
4.4) mm for the PTA and AMS groups, respectively. The
in-lesion MLD before the procedure was 0.8 ± 0.3 (range,
0.0–1.6) and 0.8 ± 0.3 (range, 0.0–1.5) mm for the PTA
and AMS groups, respectively. The mean preprocedure
Table 3 Intention-to-treat primary efﬁcacy endpoint: 6-month follow-up lesion patency based on quantitative vessel analysis (QVA) (pre- and
postprocedure lesion QVA results)
a
PTA preproc AMS preproc PTA postproc AMS postproc 6-mo QVA: PTA 6-mo QVA: AMS
No. patients 57 59 57 59 40 37
No. lesions 74 72 74 72 50 44
Patency na na na na 29/50 (58%) 14/44 (31.8%)
p = 0.0134
Non patency na na na na 21/50 (42%) 30/44 (68.2%)
Binary restenosis, mm p = 0.0134
Lesion length 12.0 ± 5.0 10.6 ± 4.9
Min–max 3.5–30.4 3.1–27.6
Stenosis diameter, mm Mean ± SD 68.7 ± 11.5 69.0 ± 10.7 21.9 ± 12.4 15.1 ± 10.2 47.8 ± 22.7 66.4 ± 27.1
(Min–max) (51.4–100) (51.3–100) (–7.2–53.6) (-18.4–38.9) (3.8–100) (2.5–100)
MLD, mm Mean 0.8 ± 0.3 0.8 ± 0.3 2.1 ± 0.5 2.2 ± 0.4 1.4 ± 0.7 0.9 ± 0.7
(Min–max) (0.0–1.6) (0.0–1.5) (1.0–3.2) (1.4–3.4) (0.0–2.9) (0.0–2.9)
p = 0.0009
RVD, mm Mean 2.7 ± 0.5 2.6 ± 0.5 2.7 ± 0.5 2.6 ± 0.5 2.7 ± 0.5 2.6 ± 0.5
(Min–max) (1.4–4.4) (1.5–4.4) (1.5–4.6) (1.5–4.6) (1.8–4.5) (1.9–3.9)
Late lumen loss, mm Mean ± SD na na na na 0.7 ± 0.7 1.4 ± 0.8
(Min–max) (-0.3–2.9) (-0.4–2.9)
p = 0.0001
Note: PTA, percutaneous transluminal angioplasty; preproc, preprocedure; AMS, absorbable metal stent; postproc, postprocedure; MLD,
minimal lumen diameter; RVD, reference vessel diameter
a For three lesions (one PTA patient and two AMS patients), angiographic procedure data were not available
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123percentage diameter stenosis measured by QVA was
69 ± 12% (range, 51–100%) and 69 ± 11% (range, 51–
100%) for the PTA and AMS groups, respectively. The
mean lesion length was 12.0 ± 5.0 (range, 3.5–30.4) mm
in the PTA group and 10.6 ± 4.9 (range, 3.1–27.6) mm in
the AMS group. Lesion location distribution over the
anterior tibial artery, tibioﬁbular trunk, ﬁbular artery, and
posterior tibial artery was 42.7%, 22.7%, 26.7%, and 8.0%,
respectively, in the PTA group and, 44.6%, 17.6%, 28.4%,
and 8.1%, respectively, for the AMS group (see Table 4).
In one lesion (1.4%) in the AMS group, another lesion
location was documented as popliteal. In total, 45.3% and
48.6% of lesions in the PTA and AMS groups were
calciﬁed.
AsshowninFig. 1,sevenPTAgrouppatients(7/57)with
11 lesions (11/75) crossed over to the other treatment (OT)
arm due to dissections in at least one of the lesions and, in
the case of one patient, due to signiﬁcant residual stenosis.
These patients were included in the PTA ? AMS group,
which isnot considered inthe OTdata analysisinthis paper.
One patient randomized for stenting (1/60) with a double
lesion (2/74) underwent implantation of a nonstudy stent
(self-expanding) due to severe tortuosity of the iliac artery.
Therefore, this patient is not considered in the OT analysis.
The ﬁnal OT cohort consisted of 50 patients with 64 lesions
treated with PTA only and 59 patients with 72 lesions who
underwent implantation of the study stent. Therefore, ITT
procedural success, which was based on visual assessment,
was achieved in 60 of 60 patients in the AMS group (100%)
and in 55 of 57 patients for the PTA group (96.4%). For one
PTA lesion, data on procedural success were not provided
by the investigator. In a conservative manner, this patient
was considered a nonsuccess. The OT procedural success
was 96.0% (48/50) and 100% (59/59) of patients in the PTA
and AMS arms, respectively. Procedural angiographic
images of three lesions (one PTA, two AMS) were not made
available by the investigator.
The primary safety endpoint, i.e., absence of major
amputation and/or death within 30 days after index inter-
vention was not signiﬁcantly different between the AMS
study group and the PTA control group (Table 5). At
1 month, a major amputation, deﬁned as amputation at or
above the ankle, was performed in four patients: two in the
group of patients randomized to PTA alone (2/57) and two
in the AMS randomized arm (2/60). One of 57 PTA
patients and 1 of 60 AMS patients died before the time of
1-month follow-up. The ITT analysis of the complication
rate within 30 days yielded values of 5.3% (3/57) and 5.0%
(3/60) in patients randomized for PTA alone and PTA
followed by AMS implantation, respectively (p = 1.0).
The corresponding complication rates by OT analysis were
6.0% (3/50) and 5.1% (3/59), respectively (p = 1.0).
The study’s primary efﬁcacy endpoint was the 6-month
angiographic patency rate as conﬁrmed by core-lab QVA
(Table 3). Six-month QVA results (regular or delayed
follow-up or clinically indicated visits) were available for
50 PTA lesions (40 patients) and 44 AMS lesions (37
patients) as presented in Table 3. The 6-month angio-
graphic patency rate on an ITT basis was 58.0% (29/50
lesions) for the PTA and 31.8% (14/44 lesions) for the
AMS (p = 0.013) group. Corresponding angiographic
patency rates by OT analysis were 63.4% (26/41 lesions)
and 31.8% (14/44 lesions) for PTA and AMS, respectively
(p = 0.005).
Table 4 Lesion morphology characterization preprocedure
a
PTA only AMS only p-value
Lesion site
Anterior tibial artery 32/75 (42.7%) 33/74 (44.6%) 0.90
b
Tibioﬁbular trunk 17/75 (22.7%) 13/74 (17.6%)
Fibular artery 20/75 (26.7%) 21/74 (28.4%)
Posterior tibial artery 6/75 (8.0%) 6/74 (8.1%)
Other 0/75 1/74 (1.4%)
No. of lesions treated
1 39/57 (68.4%) 46/60 (76.7%) 0.41
b
2 in 1 limb 18/57 (31.6%) 14/60 (23.3%)
2 in 2 limbs 0 0
Calciﬁcation 34/75 (45.3%) 36/74 (48.6%) 0.744
b
Note: PTA, percutaneous transluminal angioplasty; AMS, absorbable
metal stent
a For three lesions (one PTA patient and two AMS patients),
angiographic procedure data were not available
b Fisher test
Table 5 Primary safety endpoint: patient complication rate at 1-month follow-up
Complication Intention to treat (ITT) On-treatment (OT)
PTA AMS p-value PTA AMS p-value
Major amputation 2/57 (3.5%) 2/60 (3.3%) 1.0
a 2/50 (4.0%) 2/59 (3.4%) 1.0
a
Death 1/57 (1.8%) 1/60 (1.7%) 1/50 (2.0%) 1/59 (1.7%)
Total 3/57 (5.3%) 3/60 (5.0%) 3/50 (6.0%) 3/59 (5.1%)
Note: PTA, percutaneous transluminal angioplasty; AMS, absorbable metal stent
a Fisher’s exact test, two-sided
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123The mean LLL at 6-month follow-up was, according to
ITT, 0.7 ± 0.7 and 1.4 ± 0.8 mm, in PTA and AMS
patients, respectively (p\0.0001). By OT analysis, the
corresponding LLL mean values were 0.6 ± 0.7 and
1.4 ± 0.8 mm (p\0.0001).
Kaplan–Meier estimation of the primary patency rate, as
measured based on CFDU values as stipulated in the sec-
ondary endpoints, revealed a 6-month primary patency on
an ITT basis (Fig. 3) of 88.1% for PTA only and of 80.2%
for AMS implantation (p = 0.270). The corresponding
rates for the OT analysis were 96.5% and 79.8%
(p = 0.017).
In comparison, the Kaplan–Meier analysis of the QVA
measurements resulted in an ITT-based primary patency
(Fig. 4) of 61.2% after PTA and 47.2% after AMS
(p = 0.180) treatment. The OT primary patency rate was
70.3% for patients treated with PTA alone and 45.2% for
patients stented with the AMS (p = 0.037).
According to the Kaplan–Meier estimation, 6-month
cumulative patient limb salvage rates (Fig. 5) were calcu-
lated on an ITT basis as 92.4% and 87.6% for PTA and
AMS, respectively (p = 0.434). Corresponding OT 6-
month limb salvage rates were 91.2% and 87.3%, respec-
tively (p = 0.559).
The Kaplan–Meier estimate shows a 6-month survival
rate of 92.5% and 91.3% for patients with PTA as ITT and
AMS as ITT, respectively (p = 0.891), as presented in
Fig. 6. By OT analysis the corresponding rates were 93.6%
and 91.1%, respectively (p = 0.984).
Considering the ITT analysis, the incidence of TLR at
6 months was 16.0% (12/75) in the PTA group and 31.1%
(23/74) in the AMS group (p = 0.052), where, for PTA,
66.7% (8/12) and, for AMS, 78.3% (18/23) of lesion
revascularizations were clinically indicated. By OT anal-
ysis, the corresponding TLR incidences were 10.9% (7/64)
and 31.9% (23/72), respectively (p = 0.004), with clinical
indication for reintervention in 71.4% (5/7) of PTA and
78.3% (18/23) of AMS lesions.
Clinical follow-up at 6 months was assessed in 41 of 57
(71.9%) and 39 of 60 (65.0%) initially enrolled PTA and
AMS patients, respectively. The rate of patients who
refused the 6-month angiogram was relatively high in both
groups. Reasons for declination were diverse: patient
Fig. 3 Kaplan–Meier estimation (life-table method) of primary
patency rate. Lesion-based color ﬂow Doppler ultrasound, ITT
analysis
Fig. 4 Kaplan–Meier estimation (life-table method) of patency
measured by quantitative vascular angiography. Lesion-based ITT
analysis
Fig. 5 Kaplan–Meier estimation (life-table method) of limb salvage.
ITT analysis
Fig. 6 Kaplan–Meier estimation (life-table method) for survival-
death. ITT analysis
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123renunciation to repeat angiography (16 patients), patient
death (9 patients), major amputation (7 patients), health
issues making the angiographic control problematic (5
patients), and difﬁculties analyzing angiograms at the core
lab (3 patients). The patient’s 6-month clinical status was
assessed by the evolution of the Rutherford category, and
ITT results are summarized in Fig. 7. An improvement by
at least one Rutherford category was observed in a total of
27 of 41 (65.9%) PTA and 27 of 39 (69.2%) AMS patients,
without a statistically signiﬁcant difference between treat-
ment modalities, by either ITT or OT analysis.
The mean resting ankle-brachial index (ABI) at baseline
in PTA and AMS arms was 0.7 ± 0.3 and 0.8 ± 0.5,
respectively (ITT data). It increased signiﬁcantly, to
1.0 ± 0.2 and 1.0 ± 0.4 at 24 h after endovascular treat-
ments and to 0.9 ± 0.3 and 0.9 ± 0.4 at 6-month follow-
up, respectively.
Discussion
The AMS INSIGHT is the ﬁrst to compare, in a random-
ized controlled setting, the safety and efﬁcacy of the
implantation of a balloon-expandable absorbable stent in
the infrapopliteal bed. Earlier investigations have shown
that the BIOTRONIK AG-developed bioabsorbable Mg-
alloy stent is safe for use in infrapopliteal vessels and that it
performed as intended. This study has succeeded in prov-
ing the safety of AMS technology (primary safety
endpoint). The 30-day complication rate, as deﬁned by the
occurrence of major amputation and/or death, of patients
treated with AMS (ITT, 5.0%) was not signiﬁcantly dif-
ferent (p = 1.0) from the rate fr those treated with PTA
alone (ITT, 5.3%).
Although the safety of the AMS technology has been
shown, this study failed to prove the efﬁcacy of the tested
ﬁrst-generation AMS. The results of the core-lab QVA
even show that the 6-month outcome of PTA followed by
AMS implantation does not equal the outcome after PTA
alone. On n ITT basis the 6-month angiographic patency
rate was signiﬁcantly inferior (p = 0.013) for lesions
treated with AMS (31.8%) compared to those treated with
PTA alone (58.0%).
To date, only limited comparative QVA data for below-
the-knee arteries are available in the literature. The 6-
month binary restenosis rate after AMS was 68.2% (ITT),
which is higher than restenosis rates published by Siablis
et al. [6] and Scheinert et al. [8]comparing the effect of
bare metal stents (BMSs) versus drug-eluting stents in the
infrapopliteal bed. Siablis et al. reported a 55.3% binary
restenosis rate 6 months after BMS and 4.0% after Siroli-
mus Eluting Stent implantation [6], while Scheinert et al.
found a 6-month binary restenosis rate of 39.1% after
coronary-type BMS and 0% after drug-eluting stent
implantation [8]. In a single-arm controlled study published
by Bosiers et al. [9], a 12-month binary restenosis rate of
20.45% was seen after the implantation of nitinol self-
expanding stents in the same bed. The 6-month binary
restenosis rate of the PTA control arm of the AMS
INSIGHT (ITT, 42.0%) scores within the range of the
published data for coronary-type BMS in the infrapopliteal
region: 55.3% by Siablis et al. [6] and 39.1% by Scheinert
et al. [8]. As reported in Table 3, postprocedural MLD was
seen to be 2.2 ± 0.4 mm in the patient cohort receiving
ﬁrst-generation AMSs either /3.0 or /3.5 mm in diameter.
The low postprocedural MLD might be attributed to the
inadeaquate radial force of the ﬁrst-generation AMS to
withstand the initial vessel recoil.
As shown in Fig. 8, there is a signiﬁcant difference
in the outcomes based on CFDU versus angiography
(QVA). It was seen that there is no correspondence
between the outcomes of both investigation methods. The
untransformed values correlate signiﬁcantly (r = 0.69,
Fig. 7 Change in Rutherford category baseline vs. 6-month follow-
up. ITT analysis
Fig. 8 Color ﬂow Dopper ultrasound (CFDU) and quantitative vessel
analysis patency correlation. The untransformed values correlate
signiﬁcantly (r = 0.69, p\0.001), but the plot reveals a systematic
underestimation by the CFDU method
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123p\0.001), but the Bland-Altman plot reveals a systematic
overestimation by CFDU. Both methods differ signiﬁ-
cantly in their mean values (mean difference = 11.6). A
signiﬁcant number of patients diagnosed by CFDU to
have\50% restenosis (PVR\2.4) were observed to have
signiﬁcant restenosis measured by angiography. Other
lesions with CFDU values indicating signiﬁcant restenosis
were shown to be well patent on angiographic core-lab
control. Therefore it was decided to add a Kaplan–Meier
estimation of primary patency based on the angiographic
ﬁndings as provided by the core lab. A similar angio-
graphic primary patency curve was ﬁrst published by
Siablis et al. [6] after the initiation of the AMS INSIGHT
and has been used in different publications since then
[4, 18, 25]. Two recent publications [26, 27] conﬁrmed our
ﬁnding that, although there is good agreement between
CFDU and angiography in lower limb artery disease in
general, there is only poor agreement in infrapopliteal
regions.
Considering the Kaplan–Meier angiographic primary
patency curves as an efﬁcacy reference, the 6-month out-
come of the AMS INSIGHT can be compared to other
infrapopliteal PTA and/or stent study ﬁndings. The 6-
month angiographic patency rate for the PTA (ITT, 61.2%)
group is higher than the one published by Rand et al.,
which was only 45.6% for the PTA-only group [4]. The 6-
month angiographic primary patency of the AMS (ITT,
47.2%) is well below the rates published for permanent
balloon-expandable stent types in the crural arteries. A 6-
month angiographic patency rate of 68.1% after BMS was
found by Siablis et al. [6], and 79.7% was found by Rand
et al. [4] after PCS.
As could be expected the limb salvage rates in the AMS
trial are within the range of previously published studies on
infrapopliteal endovascular interventions. In general, the 6-
month limb salvage rates are far higher than according
patency values and mostly lie at about 90% [9]. It could be
understood that a nonhealing wound or viable limb does
not require a full 6-month patency or reperfusion time to
generate optimal healing or symptom relief. It is believed
that, in combination with restarting the patient’s daily life
activities, an approximate reperfusion lasting about
3 months would be sufﬁcient for 6-month limb salvage.
Nevertheless, long-term limb salvage undoubtedly beneﬁts
from extended patency of the treated lesion.
The ﬁndings from the AMS INSIGHT did not support
the positive clinical outcome of the initial AMS ﬁndings in
a small cohort of patients [17–19] and indicate that the
current-generation stent does not meet the efﬁcacy criteria.
Therefore, the stent needs to be improved and re-evaluated
before commercial use can be an option. The following
criteria are believed to cause the problem. In the AMS
INSIGHT, core-lab QVA showed a discrepancy between
inclusion criteria and available stent sizes. The reference
vessel diameter in the AMS randomized group was
2.6 ± 0.5 (range, 1.5–4.4) mm. Therefore, many lesions
were too small in diameter and longer than the stent length.
Hence, the lesion did not match the available nominal
AMS sizes. It is possible that oversizing causing vessel
trauma was the case. A small magniﬁcation error due to the
ruler on the table can only partially explain the observed
mismatch. New sizes and longer lengths for AMSs should
be developed for below-the-knee use. This ﬁrst-generation
AMS is probably being absorbed too fast, inducing loss of
stent scaffolding properties. The AMS PROGRESS [13]
coronary study suggested fast degradation that initiated
immediately after deployment, with nearly fully absorption
after 4 months. Thus the restenosis in the AMS group can
be attributed to early recoil in addition to neointima for-
mation. To improve clinical results with the AMS
technology, a second-generation AMS is under develop-
ment, with optimization of the Mg alloy and the stent
design resulting in a longer degradation time and increased
radial force and stent sizes should be better adapted to
peripheral lesions.
Study Limitations
The major limitation of the AMS INSIGHT was the
selection of a CFDU investigation to determine the primary
patency. During the course of the trial, it was discovered
and evidence was obtained on hand that CFDU has only
limited relevance in the diagnosis of infrapopliteal disease
[23]. Therefore, it was decided during data analysis to use
angiographic primary patency as the main comparator with
other trials.
A second limitation of the trial might be the initially
very strict angiographic inclusion criteria. It was decided,
in order to have a good match with the limited length
variations of the available AMS devices (the initial maxi-
mal stent length was 15 mm; later, 20-mm-long stents also
became available) and to have each lesion covered by
maximally one stent, to limit the maximal lesion length to
15 mm initially and to 20 mm later. Furthermore, it was
decided to include only patients with a maximum of two
lesions in one or more infrapopliteal vessel. As the
majority of CLI patients represent with complex multilevel
disease, it was the experience of the different investigators
that these criteria allowed the inclusion of only a very
restricted number of patients, not accurately reﬂecting the
real-world CLI population. Therefore it was decided to
amend the protocol and also allow the PTA treatment of
other infrapopliteal lesions in nontarget vessels outside of
the current study.
Third, repeated angiographic imaging could not be
obtained in 34% of the study population. Similar high
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123dropout rates have been published in other CLI studies [4,
25] and can be considered acceptable for this fragile
population.
Conclusion
The AMS INSIGHT has shown that the AMS technology is
a safe technique to use for treating peripheral arterial dis-
ease, but that the tested current-generation AMS did not
show efﬁcacy in long-term patency over standard PTA in
infrapopliteal vessels. Therefore, important stent design
modiﬁcations are required and further clinical trials should
be performed before potential widespread application of
the technology.
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